| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Center for Stroke Research, Department of Neurological Sciences (Drs. Nyenhuis, Gorelick, and Garron), and Psychology Department (Drs. Nyenhuis and Garron), Rush–Presbyterian–St. Luke’s Medical Center; and School of Public Health (Dr. Freels), University of Illinois, Chicago.
Address correspondence and reprint requests to Dr. David L. Nyenhuis, Center for Stroke Research, Rush–Presbyterian–St. Luke’s Medical Center, 1645 West Jackson Boulevard, Suite 400, Chicago, IL 60612; e-mail: dnyenhui{at}rush.edu
Objective: To compare the rates of cognitive and functional decline in African American patients diagnosed at baseline with vascular dementia (VaD) (n = 79), AD (n = 113), or stroke without dementia (SWD) (n = 56) and followed for up to 7 years with annual neuropsychological and other examinations.
Methods: Study patients were diagnosed using established criteria for dementia and were administered cognitive screening, functional screening, and neuropsychological measures. Baseline dementia severity was rated using the Clinical Dementia Rating Scale. Random effects modeling was used to examine rates of decline and to compare the rates of decline in the three groups.
Results: Both patients with VaD and those with AD showed significant cognitive and functional decline during follow-up; patients with VaD declined at a slower rate than patients with AD; and patients diagnosed with SWD at baseline did not show cognitive or functional decline during follow-up.
Conclusions: Patients with VaD decline at a slower rate than patients with AD. Patients who do not meet criteria for dementia soon after stroke may not be at high risk for developing dementia. Future studies are needed to follow VaD patients with longitudinal, specialized MR protocols, concurrent neuropsychological examinations, and neuropathologic examination to determine possible neuroimaging predictors of progressive cognitive and functional decline and to assess the contribution of Alzheimer’s pathology to decline in patients diagnosed with VaD.
This article has been cited by other articles:
|
|
 |
|
  A Bruandet, F Richard, S Bombois, C A Maurage, V Deramecourt, F Lebert, P Amouyel, and F Pasquier Alzheimer disease with cerebrovascular disease and vascular dementia: clinical features and course compared with Alzheimer disease J. Neurol. Neurosurg. Psychiatry, February 1, 2009; 80(2): 133 - 139. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. K. Srikanth, S. J. Quinn, G. A. Donnan, M. M. Saling, and A. G. Thrift Long-Term Cognitive Transitions, Rates of Cognitive Change, and Predictors of Incident Dementia in a Population-Based First-Ever Stroke Cohort Stroke, October 1, 2006; 37(10): 2479 - 2483. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Pytel, E. J. Cochran, G. Bonner, D. L. Nyenhuis, C. Thomas, and P. B. Gorelick Vascular and Alzheimer-type pathology in an autopsy study of African-Americans Neurology, February 14, 2006; 66(3): 433 - 435. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. INUI, A. ASAKAWA, C. Y. BOWERS, G. MANTOVANI, A. LAVIANO, M. M. MEGUID, and M. FUJIMIYA Ghrelin, appetite, and gastric motility: the emerging role of the stomach as an endocrine organ FASEB J, March 1, 2004; 18(3): 439 - 456. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Scanlan, L. Dufourny, and D. C. Skinner Somatostatin-14 Neurons in the Ovine Hypothalamus: Colocalization with Estrogen Receptor {alpha} and Somatostatin-28(1-12) Immunoreactivity, and Activation in Response to Estradiol Biol Reprod, October 1, 2003; 69(4): 1318 - 1324. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Barrett, D. L. Nyenhuis, and P. B. Gorelick Cognitive and functional decline in African Americans with VaD, AD, and stroke without dementia Neurology, August 13, 2002; 59(3): 475 - 476. [Full Text] [PDF]
|
|
Read all Correspondence
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
